Mark A. Hillman - Hillman Value Fund Investment Strategy & Portfolio Analysis
How Hillman Value Fund allocates capital, manages risk, and constructs its portfolio — based on SEC 13F filings.
According to the SEC 13F filed on Aug 14, 2026, Mark A. Hillman's Hillman Value Fund portfolio reflects a quant / systematic investor approach across 53 reported 13F positions as of quarter-end Jun 30, 2026. Portfolio returns are distributed across holdings, with the top five positions representing approximately 20% of total exposure. Across 53 reported holdings, economic exposure is broadly distributed across healthcare, consumer defensive companies, and technology without dominant single-name concentration. Exposure to high-growth and technology-oriented segments is moderate relative to peers, with performance weighted across healthcare, consumer staples, and communication services. The portfolio exhibits extremely low turnover, reinforcing a patient, conviction-led investment approach. Distinctive traits include Long-Term Holder, Broadly Diversified, Economically Diversified.
Investment Style
Value, growth, quality, and behavioral classification from latest 13F holdings.
Primary type: Quant / Systematic Investor
Traits: Long-Term Holder, Broadly Diversified, Economically Diversified, Structurally Diversified
Turnover profile
Buy & Hold
Holding horizon
Long-Term
Portfolio Construction
Concentration and position sizing in the latest filing.
Portfolio construction is lowly concentrated: top three names represent 12.0% of assets, top five 19.5%, and the largest single position is 4.3%.
Top 3 weight
12.0%
Top 5 weight
19.5%
Top 10 weight
37.3%
Largest position
4.3%
Top holdings: CVS Health Corporation, Biogen Inc., Warner Bros. Discovery, Inc. -, Baxter International Inc., International Flavors & Fragran — view full holdings
Sector Preferences
Where capital is allocated by sector.
Capital is tilted toward Healthcare and Consumer Defensive, with 10 sectors represented in the latest filing.
Leading sectors: Healthcare, Consumer Defensive, Technology
Risk Framework
Concentration, diversification, and turnover tolerance.
This investor accepts low single-name risk (largest position 4.3%, top ten 37.3%) and high economic diversification (HHI 0.01). Turnover tolerance maps to a buy & hold profile.
Largest position
4.3%
Top 10 weight
37.3%
Max sector
31.7%
Diversification
High
Strategy Evolution
How the strategy changed between the two most recent filing periods.
Mar 31, 2026 → Jun 30, 2026
- Position count decreased from 56 to 53 (-3 names).
- Top-five concentration rose from 18.7% to 19.5%.
- Largest holding changed from Biogen Inc. to CVS Health Corporation.
- Quarter-over-quarter portfolio weight turnover: 9.5%.
For trade-level changes, see the Activity page. View activity.
Similar Investors
Peer group with comparable portfolio behavior.
Similar-investor comparisons are coming soon.